Notice of Interim Results

Released : 09.03.2017

RNS Number : 9163Y
Allergy Therapeutics PLC
09 March 2017
 

 

Allergy Therapeutics plc

("Allergy Therapeutics" or the "Group")

 

Notice of Interim Results

 

9 March 2017 Allergy Therapeutics (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, will issue its interim results for the six months ended 31 December 2016 on Wednesday 29 March 2017.

 

Manuel Llobet, Chief Executive Officer, and Nick Wykeman, Finance Director, will hold a presentation and conference call for analysts on the day of results at 9:00am at Panmure Gordon, One New Change, London, EC4M 9AF.

 

Please contact Consilium Strategic Communications for further details.

 

- ENDS -

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Nick Wykeman, Finance Director

 

Panmure Gordon

+44 (0) 20 7886 2500

Freddy Crossley / Duncan Monteith, Corporate Finance

Tom Salvesen, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott / Ivar Milligan

allergytherapeutics@consilium-comms.com

 

Note to editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international specialty pharmaceutical group focussed on the treatment and diagnosis of allergic disorders including immunotherapy vaccines that cure disease.  The Group sells proprietary products and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries.

 

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with MHRA-approved manufacturing facilities.  The Group employs c.495 employees and is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NORQVLFBDXFZBBE